Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7121523 | 1.00 | PLG (0.42) | PLGMAPTATMNPSR1P2RY14 | |
| SCHEMBL7121518 | 1.00 | PLG (0.42) | PLGMAPTATMNPSR1P2RY14 | |
| SCHEMBL30608334 | 0.83 | PLG (0.41) | PLGMAPTP2RY14HTR2CCYP3A4 | |
| SCHEMBL13161383 | 0.83 | HTR3A (0.55) | PLGP2RY14HTR2CPRCPHTR3A | |
| SCHEMBL5011948 | 0.82 | SLC18A3 (0.55) | PLGP2RY14SLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2159262 | 0.81 | HTR3A (0.53) | PLGP2RY14HTR2CHTR3A | |
| SCHEMBL23858275 | 0.80 | HTR2C (0.64) | PLGP2RY14HTR2CKDM1A | |
| SCHEMBL12488729 | 0.80 | KCNH2 (0.46) | PLGP2RY14HTR2C | |
| SCHEMBL23873227 | 0.80 | HTR2C (0.46) | PLGP2RY14HTR2C | |
| SCHEMBL18618469 | 0.80 | KDM1A (0.44) | PLGHTR2CGID4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092733-A1 | Process for preparing trans-2,4-disubstituted piperidines | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| EP-1244622-A1 | A PROCESS FOR PREPARING TRANS-2,4-DISUBSTITUTED PIPERIDINES | ELI LILLY AND COMPANY (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001046143-A1 | A PROCESS FOR PREPARING TRANS-2,4-DISUBSTITUTED PIPERIDINES | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092733-A1 | Process for preparing trans-2,4-disubstituted piperidines | CYP4B1, CYP1A1, CYP3A4 | PLG 4063/4885MAPT 2868/4885ATM 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.